485.8

+0.96%↑

SANES

10.682

+2.89%↑

SAF

317.7

+2.38%↑

BBVA

20.08

+2.08%↑

BNP

91.17

+1.66%↑

485.8

+0.96%↑

SANES

10.682

+2.89%↑

SAF

317.7

+2.38%↑

BBVA

20.08

+2.08%↑

BNP

91.17

+1.66%↑

485.8

+0.96%↑

SANES

10.682

+2.89%↑

SAF

317.7

+2.38%↑

BBVA

20.08

+2.08%↑

BNP

91.17

+1.66%↑

485.8

+0.96%↑

SANES

10.682

+2.89%↑

SAF

317.7

+2.38%↑

BBVA

20.08

+2.08%↑

BNP

91.17

+1.66%↑

485.8

+0.96%↑

SANES

10.682

+2.89%↑

SAF

317.7

+2.38%↑

BBVA

20.08

+2.08%↑

BNP

91.17

+1.66%↑

Home・Akcijų sąrašas・Sartorius Stedim Biotech.

Sartorius Stedim Biotech.

Uždarymo kaina

SektoriusFinansų sektorius

181.8 5.21

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

173

Max

182.2

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-17M 47M
Pardavimai	67M 772M
P/E Sektoriaus vid.	62.169 37.917
Dividendų pajamingumas	0.41
Pelno marža	6.125
Darbuotojai	9,753
EBITDA	-19M 199M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+36.82% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	0.41% 4.79%
Kitas uždarbis	2026-04-23

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-1.8B 16B
Ankstesnė atidarymo kaina	176.59
Ankstesnė uždarymo kaina	181.8

Naujienos nuotaikos

By Acuity

10%

90%

6 / 440 reitingas Finance

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

202.7 / 211.7 Palaikymas ir pasipriešinimas

Sartorius Stedim Biotech. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-13 23:25; UTC

Svarbiausios naujienos

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

2026-04-13 22:45; UTC

Svarbiausios naujienos

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

2026-04-13 18:03; UTC

Uždarbis

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

2026-04-13 23:58; UTC

Uždarbis

Review & Preview: Earnings Time -- Barrons.com

2026-04-13 23:49; UTC

Rinkos pokalbiai

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

2026-04-13 23:33; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Edges Higher Amid Dollar Weakness -- Market Talk

2026-04-13 23:20; UTC

Rinkos pokalbiai

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

2026-04-13 23:01; UTC

Uždarbis

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

2026-04-13 23:01; UTC

Uždarbis

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

2026-04-13 23:01; UTC

Uždarbis

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

2026-04-13 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

2026-04-13 21:53; UTC

Uždarbis

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

2026-04-13 21:53; UTC

Uždarbis

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

2026-04-13 21:53; UTC

Uždarbis

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

2026-04-13 21:53; UTC

Uždarbis

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

2026-04-13 21:26; UTC

Svarbiausios naujienos

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

2026-04-13 21:23; UTC

Uždarbis

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

2026-04-13 21:16; UTC

Uždarbis

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

2026-04-13 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-04-13 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-04-13 20:34; UTC

Uždarbis

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

2026-04-13 20:34; UTC

Uždarbis

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

2026-04-13 20:34; UTC

Uždarbis

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

2026-04-13 19:59; UTC

Rinkos pokalbiai

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

2026-04-13 19:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

2026-04-13 19:27; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Correction to Precious Metals Market Talk on April 9

2026-04-13 19:14; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

2026-04-13 18:59; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

2026-04-13 18:59; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

2026-04-13 18:43; UTC

Rinkos pokalbiai

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Akcijų palyginimas

Kainos pokytis

Sartorius Stedim Biotech. Prognozė

Kainos tikslas

By TipRanks

36.82% į viršų

12 mėnesių prognozė

Vidutinis 233 EUR 36.82%

Aukščiausias 262 EUR

Žemiausias 210 EUR

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sartorius Stedim Biotech. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių Sartorius Stedim Biotech. akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

202.7 / 211.7Palaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Rinkos nuotaikos

By Acuity

6 / 440 reitingas Finansų sektorius

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.